{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["12(9)"],"submitter":["Perez-Martinez L"],"pubmed_abstract":["<h4>Background</h4>As age increases, the risk of developing fragility also increases. Improving the knowledge of frailty could contribute to maintaining the functional ability of elderly people. Interleukin (IL)-10 homozygous knockout mice (IL-10<sup>tm/tm</sup> [IL10KO]) constitute an excellent tool for the study of frailty. Because patients with frailty demonstrate an overexpression of CCR5, rapamycin (RAPA) and/or maraviroc (MVC), two molecules able to decrease CCR5 expression, were evaluated.<h4>Results</h4>Muscle myostatin was reduced in all the therapeutic groups but the MVC group (p <0.001 for RAPA and MVC-RAPA) and in serum samples (p <0.01 for all the groups). Serum CK levels were also significantly lower in MVC and RAPA groups (p <0.01 in both cases). Lower AST levels were observ"],"journal":["Aging"],"pagination":["8565-8582"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7244075"],"repository":["biostudies-literature"],"pubmed_title":["Implications of maraviroc and/or rapamycin in a mouse model of fragility."],"pmcid":["PMC7244075"],"pubmed_authors":["Carnero A","Munoz-Galvan S","Perez-Martinez L","Romero L","Rubio-Mediavilla S","Oteo JA","Verdugo-Sivianes EM","Blanco JR"],"additional_accession":[]},"is_claimable":false,"name":"Implications of maraviroc and/or rapamycin in a mouse model of fragility.","description":"<h4>Background</h4>As age increases, the risk of developing fragility also increases. Improving the knowledge of frailty could contribute to maintaining the functional ability of elderly people. Interleukin (IL)-10 homozygous knockout mice (IL-10<sup>tm/tm</sup> [IL10KO]) constitute an excellent tool for the study of frailty. Because patients with frailty demonstrate an overexpression of CCR5, rapamycin (RAPA) and/or maraviroc (MVC), two molecules able to decrease CCR5 expression, were evaluated.<h4>Results</h4>Muscle myostatin was reduced in all the therapeutic groups but the MVC group (p <0.001 for RAPA and MVC-RAPA) and in serum samples (p <0.01 for all the groups). Serum CK levels were also significantly lower in MVC and RAPA groups (p <0.01 in both cases). Lower AST levels were observ","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Apr","modification":"2025-04-18T14:36:01.65Z","creation":"2020-06-07T07:12:14Z"},"accession":"S-EPMC7244075","cross_references":{"pubmed":["32353830"],"doi":["10.18632/aging.103167"]}}